松村 保広 マツムラ ヤスヒロ
















  • 昭和56年3月

    熊本大学医学部卒業 4月同第1外科入局

  • 昭和63年3月

    同医学博士号取得 8月医学部微生物学教室助手

  • 平成元年8月


  • 平成2年9月

    英国オックスフォード大学ナフィールド病理Post Doc

  • 平成5年7月

    同上級臨床リサーチサイエンテイスト グレイドA65

  • 平成6年9月


  • 平成11年1月


  • 平成14年4月

    国立がんセンター研究所支所がん治療開発部長(現 先端医療開発センター新薬開発分野 分野長)

  • 平成24年4月


  • 平成26年4月




  1. Y. Matsumura, H. Maeda.  A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387-6392, 1986
  2. H. Maeda, Y. Matsumura, H. Kato. Purification and identification of (hydroxyprolyl3)-bradykinin in ascitic fluid from a patient with gastric cancer. J. Biol. Chem. 263, 16051-16054, 1988
  3. Y. Matsumura, M. Kimura, T. Yamamoto, H. Maeda.  Involvement of the kinin-generating cascade and enhanced vascular permeability in tumor tissue.  Jpn. J. Cancer Res. 79, 1327-1334, 1988
  4. Y. Matsumura, D. Tarin.  DNA fingerprinting survey of various human tumors and their metastasis.  Cancer Res. 52, 2174-2179, 1992
  5. Y. Matsumura, D. Tarin.  Significance of CD44 gene products for cancer diagnosis and disease evaluation.  Lancet 340, 1053-1058, 1992
  6. Y. Matsumura, D. Hanbury, J. Smith, D. Tarin.  Non-invasive detection of malignancy by identification of unusual CD44 gene activity in exfoliated cancer cells.  BMJ. 308, 619-624, 1994
  7. Y. Matsumura, M. Sugiyama, S. Matsumura, AJ. Hayle, P. Robinson, JC. Smith, D. Tarin.  Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities. J Pathol. 177, 11-20, 1995
  8. K. Yamao, Y. Matsumura, Y. Shimada, Y. Moriya, K. Sugihara, T. Akasu, S. Fujita, T. Kakizoe.  Abnormal expression of CD44 variants in the exfoliated cells in the feces of patients with colorectal cancer. Gastroenterology 114, 1196-1205, 1998
  9. Y. Tsukioka, Y. Matsumura, T. Hamaguchi, H. Koike, F. Moriyasu, T. Kakizoe.  Pharmaceutical and Biomedical Differences between Micellar Doxorubicin (NK911) and Liposomal Doxorubicin (Doxil).  Jpn. J. Cancer Res. 10, 1145-1153, 2002
  10. Y. Matsumura, M. Gotoh, K .Muro, Y. Yamada, K. Shirao, Y. Shimada, M. Okuwa, S. Matsumoto, Y. Miyata, H. Ohkura, K. Chin, S. Baba, T. Yamao, A. Kannami, Y. Takamatsu, K. Ito, K. Takahashi. Phase I and Pharmacokinetic Study of MCC-465, a doxorubicin (DXR) encapsulated in PEG-immunoliposome, in patients with metastatic stomach cancer. Annals Oncol  15, 517-525, 2004
  11. Y Matsumura, T Hamaguchi, T Ura, K Muro, Y Yamada, Y Shimada, K Shirao, T Okusaka, H Ueno, M Ikeda, N Watanabe. A phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Brit J Cancer 91, 1775-1781, 2004
  12. T Hamaguchi, Y Matsumura, M Suzuki, K Shimizu,R Goda, I Nakamura, I Nakatomi, M Yokoyama, K Kataoka and T Kakizoe. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Brit J Cancer 92, 1240-1246, 2005
  13. H Matsushita, Y Matsumura, Y Moriya, T Akasu, S Fujita, S Yamamoto, S Onouchi, N Saito, M Sugito, M Ito, T Kozu, T Minowa, S Nomura, H Tsunoda, T Kakizoe. A new methodology for isolating colonocytes from naturally evacuated feces and its clinical application to colorectal cancer diagnosis. Gastroenterology 129, 1918-1927, 2005
  14. F Koizumi, M Kitagawa, T Negishi, T Onda, S Matsmoto, T Hamaguchi, Y Matsumura. Novel SN-38-incorporated polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res 66, 10048-10056, 2006
  15. T Hamaguchi, K Kato, H Yasui, C Morizane, M Ikeda, H Ueno, K Muro, Y Yamada, T Okusaka,K Shirao, Y Shimada, H Nakahama Y Matsumura A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle Formulation. Brit J Cancer. 97, 170-176, 2007
  16. J Kuroda, J Kuratsu, M Yasunaga, Y Koga, T Sugino, Y Matsumura. Antitumor Effect of NK012, SN-38 Incorporating Polymeric Micelle on U87MG Orthotopic Glioblastoma in Mice Compared with Irinotecan in Combination with Bevacizumab. Clin Cancer Res. 16, 521-9, 2010
  17. Y Koga, M Yasunaga, A Takahashi, J Kuroda, Y Moriya, T Akasu, S Fujita, S Yamamoto, H Baba, Y Matsumura. MicroRNA Expression Profiling of Exfoliated Colonocytes Isolated from Feces for Colorectal Cancer Screening. Cancer Prev Res (Phila). 3(11), 1435-1442, 2010
  18. M Yasunaga, S Manabe, Y Matsumura.  New Concept of Cytotoxic Immunoconjugate Therapy Targeting Cancer-Induced Fibrin Clots. Cancer Sci.102, 1396-1402, 2011
  19. Y Matsumura. Cancer stromal targeting (CAST) therapy. Adv Drug Deliv Rev.  64,710-719, 2012 .
  20. Y Hisada, M Yasunaga, S Hanaoka, , Saijou. T Sugino A, Tsuji, T Saga, K Tsumoto,
    S Manabe,. J Kuroda,. J Kuratsu, Y Matsumura. Discovery of an uncovered region in fibrin clots and its clinical significance. Sci. Rep. 3, 2604,2013.
  21. M Yasunaga, M Furuta, K Ogata, Y Koga, Y Yamamoto, M Takigahira, Y Matsumura. The significance of microscopic mass spectrometry with high resolution in the visualization of drug distribution.  Sci. Rep. 3, 3050, 2013.
  22. M Yasunaga, Y Matsumura Role of SLC6A6 in promoting the survival and multidrug resistance of colorectal cancer. Sci. Rep. 4, 4852, 2014
  23. Obonai T, Fuchigami H, Furuya F, Kozuka N, Yasunaga M, Matsumura Y. Tumour imaging by detecting fibrin clots in tumour stroma with anti-fibrin Fab fragment. Sci Rep 6, 23613, 2016.
  24. Fujiwara Y, Furuta M, Manabe S, Koga Y, Yasunaga M, Matsumura Y. Imaging mass spectrometry for the exquisite design of antibody-drug conjugates. Sci Rep 6, 24954, 2016.


抗体薬物複合体(ADC)の設計開発 シーエムシー出版 2016年(監修:松村保広)


  • 2005年 日本DDS学会 永井賞
  • 2006年 国立がんセンター田宮賞



  • 日本DDS学会 副理事長
  • 日本癌学会 理事、評議員
  • 日本がん治療学会 代議員
  • 日本臨床腫瘍学会 評議員
  • 日本内科学会
  • 日本消化器病学会
  • American Society of Clinical Oncology
  • American Association of Cancer Research
  • Controlled Release Society
  • 2009年第25回日本DDS学会会長